They had experienced symptoms of polycythemia vera for an average of 7 years.
他们平均已患有真性多血症的症状达7年之久。
Objective: To investigate the role of EPO in the pathogenesis of high altitude polycythemia (HAPC).
目的：探讨EPO在高原红细胞增多症发病机制中的作用。
Neonatal low birth weights, respiratory distress syndrome and polycythemia are risk factors for THP.
新生儿低出生体质量、呼吸窘迫综合征及红细胞增多症是THP的危险因素。
Objective To characterize clinical feature of rhinorrhagia correlated with high altitude polycythemia (HAPC).
目的探讨高原红细胞增多症(HAPC)患者鼻出血的临床特点。
There were more patients complicated with hypertension and secondary polycythemia inOSAS group than in control group.
OSAS组的高血压和继发性红细胞增多症明显高于对照组。
Objective To investigate the growth of endogenous erythroid colony (EEC) in polycythemia vera (PV) patients and its clinical significance.
目的了解真性红细胞增多症(PV)患者内源性红系集落(EEC)生长情况及其临床意义。
Animals with erythroleukemia are anemic despite having a marrow filled with rubriblasts, where as those with polycythemia vera have erythrocytosis.
白血病动物虽然在骨髓充满原始红细胞却依然贫血，而真性红细胞增多症真的有很多红细胞。
Objective To study the mechanism, clinical manifestations and pathophysiological characteristics of erythromelalgia accompanying polycythemia vera.
目的研究伴发于真性红细胞增多症的红斑性肢痛症发病机制、临床表现、病理生理特点。
These results proved that polycythemia may play an important role in pathogenesis of chronic hypoxic pulmonary hypertension and cardiac hypertrophy.
以上结果表明红细胞增多可能在慢性缺氧性肺动脉高压和右室肥大发生起着重要作用。
The above results proved that polycythemia might play an important role in pathogenesis of hypoxic pulmonary hypertension and myocardial hypertrophy.
以上结果表明，红细胞增多在缺氧性肺动脉高压和右室肥大中起着重要作用。
Objective To investigate the alteration of serum thyroid hormone level in the patients with high altitude polycythemia (HAPC) and its clinical significance.
目的探讨高原红细胞增多症(HAPC)患者血清甲状腺激素的变化及其临床意义。
Results The changes of myocardial enzyme in cyanosis group with polycythemia were significantly higher than those in the group without polycythemia( P< 0 05);
结果①青紫组合并红细胞增多症者心肌酶学改变较非红细胞增多者明显升高（P＜005）；
Objective To understand the changes ofhemorheological factors in these patients with in Polycythemia Vera and study its pathology in order to find the preventive and treating methods.
目的了解真性红细胞增多症患者的血液流变学特性变化，研究其并发症的发病机理和寻找预防和治疗的方法。
Because polycythemia may require dose reductions or discontinuation of therapy, hematocrit should be obtained at baseline, 3 to 6 months after initiation of therapy, and annually thereafter.
由于红细胞增多可能需要降低剂量或停止治疗，故应在开始治疗前、初始治疗后的3 ~6个月以及随后的每年检测红细胞比积。
Because polycythemia may require dose reductions or discontinuation of therapy, hematocrit should be obtained at baseline, 3 to 6 months after initiation of therapy, and annually thereafter.
由于红细胞增多可能需要降低剂量或停止治疗，故应在开始治疗前、初始治疗后的3 ~6个月以及随后的每年检测红细胞比积。
应用推荐